Jean‐François Héron

Author

Jean‐François Héron

Also Known As

B. Chevallier, J F Heron, J F Héron, J. F. HERON, J. F. Héron, J. Heron, J.-F. Heron, J.-F. Héron, J.F. HERON, J.F. Heron

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Centre François Baclesse Institut Bergonié Centre Georges François Leclerc Centre François Baclesse Institut Gustave Roussy

About

Jean‐François Héron is an author at Centre François Baclesse specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	493
2	Cell Biology	2	2	69
3	Health Sciences	1	1	101
4	Public Health	1	1	14
5	Cellular Physiology	1	1	14

Jean‐François Héron

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. W ten Bokkel Huinink, Martin Gore, J Carmichael, Journal of Clinical Oncology	1997	681
Quality of Life in Long-Term Survivors of Testicular Cancer: A Population-Based Case-Control Study Florence Joly, Jean‐François Héron, L. Kalusinski, Journal of Clinical Oncology	2002	141
Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer F. Joly, D. Brune, J.E. Couette, Annals of Oncology Quality Of LifeUrologyRadiation MedicineHealth SciencesRadiation Therapy	1998	101
Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP Stéphane Culine, Andrew Kramar, Christine Théodore, Journal of Clinical Oncology	2008	99
Clinical Evidence for Topotecan-Paclitaxel Non–Cross-Resistance in Ovarian Cancer Martin Gore, W ten Bokkel Huinink, James Carmichael, Journal of Clinical Oncology	2001	93
Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: A double-blind, placebo-controlled, comparative study L. Goedhals, Jean‐François Héron, J.P. Kleisbauer, Annals of Oncology Emetogenic ChemotherapyOncologyMedicineMetronomic TherapyPharmacotherapy	1998	85
Oral granisetron alone and in combination with dexamethasone: A double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis Jean‐François Héron, L. Goedhals, J. P. Jordaan, Annals of Oncology OncologyCisplatin-induced EmesisMedicineDouble-blind Randomized ComparisonMetronomic Therapy	1994	75
Cost of Treating Advanced Colorectal Cancer: A Retrospective Comparison of Treatment Regimens Paul J. Ross, Jean‐François Héron, David Cunningham European Journal of Cancer Surgical OncologyOncologyRetrospective ComparisonHealth EconomicsGastrointestinal Oncology	1996	54
Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment Marie Villedieu, E. Deslandes, Marilyne Duval, Gynecologic Oncology Progressive AlterationOncologyMedicineP38 ActivationGynecology	2006	53
[Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2b-N1, T3b, MO)]. J Chauvergne, J Rohart, Jean‐François Héron, PubMed	1990	28

Page 1